Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Authors

null

Van K. Morris II

Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

Van K. Morris II, Greg Yothers , Scott Kopetz , Shannon L Puhalla , Peter C. Lucas , Atif Iqbal , Patrick M Boland , Dustin A. Deming , Aaron James Scott , Howard John Lim , Theodore S. Hong , Norman Wolmark , Thomas J. George

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Clinical Trial Registration Number

NCT04068103

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS3625)

DOI

10.1200/JCO.2023.41.16_suppl.TPS3625

Abstract #

TPS3625

Poster Bd #

324b

Abstract Disclosures

Similar Posters

First Author: Van K. Morris II

First Author: Van K. Morris II

First Author: Van K. Morris II

First Author: Van K. Morris II